Document is current

Article History

Received: 31 December 2023

Accepted: 3 May 2024

First Online: 9 May 2024

Declarations

:

: This study was approved by the Institutional Review Board and Protocol Review Committee of the Korean Cancer Study Group (protocol number AL22-09) and by the review boards of all 31 institutions. Informed consent will be obtained from all patients and/or their legal guardian(s) in compliance with the Declaration of Helsinki.

: Not applicable.

: SYK receives research funding from Roche/Genentech. JHK receives research funding from Eisai, Ono Pharmaceutical, and Roche. SRP has receives research funding from ImmuneOncia Therapeutics, ONO Pharma Korea, and Incyte. SL (Soohyeon Lee) has stock and other ownership interests of Celgene/Bristol-Myers Squibb and Pfizer and receives research funding from Jeil Pharmaceutical Co. SL (Se-Hoon Lee) receives research funding from AstraZeneca, Lunit, and Merck. TMK has consulting or advisory roles outside this work, related to Amgen, AstraZeneca/MedImmune, Boryung, Daiichi-Sankyo, HK inno.N, IMBDx. Inc., Janssen, Novartis, Regeneron, Roche/Genentech, Samsung Bioepis, Takeda, and Yuhan. HRK received honoraria from AstraZeneca, Bristol Myers Squibb, Genentech/Roche, stock ownership in Bridgebio Therapeutics; served as a consultation or advisory role for Bayer, AstraZeneca, Bristol Myers Squibb, Takeda, and Yuhan; and received research funding from the Yonsei Lee Youn Jae Fellowship outside of the current work. YC is employed and has stock and other ownership interests with Abion. JBA receives research funding from Sanofi. The remaining authors declare no conflict of interest that are relevant to the content of this article.